Apigenin
flavonoid
What it isDietary flavonoid with weak benzodiazepine-site activity, found in chamomile.
Why this oneIt is the proposed basis for chamomile’s mild calming effect.
What limits itWeak CYP inhibition means supplement doses can interact; clinical evidence is thin.
FDA-approved for
- dietary flavonoid (no approved indication)
Off-label
- sedation/anxiolysis (chamomile constituent; limited evidence)
NO BOXED WARNINGS
Principal riskWeak CYP inhibition at supplement doses